doi: 10.1002/sim.861.
Bayesian cost-effectiveness analysis from clinical trial data
Affiliations
- PMID: 11241573
- DOI: 10.1002/sim.861
Item in Clipboard
Bayesian cost-effectiveness analysis from clinical trial data
Stat Med.
.
Abstract
A key tool for assessing the relative cost-effectiveness of two treatments in health economics is the incremental C/E acceptability curve. We present Bayesian computations for this curve in the case where data on both costs and efficacy are available from a clinical trial. Analysis is given under various formulations of prior information. A case study is analysed in which reasonable prior information is shown to strengthen substantially the posterior inference, leading to a more conclusive assessment of cost-effectiveness. Calculations can be performed using readily available Bayesian software.
Copyright 2001 John Wiley & Sons, Ltd.
Similar articles
-
A Bayesian analysis of pharmacoeconomic data from a clinical trial on schizophrenia.Stat Med. 2003 Mar 30;22(6):1025-39. doi: 10.1002/sim.1458. Stat Med. 2003. PMID: 12627416
-
A Bayesian model averaging approach for cost-effectiveness analyses.Health Econ. 2009 Jul;18(7):807-21. doi: 10.1002/hec.1404. Health Econ. 2009. PMID: 18792078
-
Semi-parametric modelling for costs of health care technologies.Stat Med. 2005 Oct 30;24(20):3171-84. doi: 10.1002/sim.2012. Stat Med. 2005. PMID: 15568210
-
Cost-effectiveness as an outcome in randomized clinical trials.Clin Trials. 2006;3(6):543-51. doi: 10.1177/1740774506073105. Clin Trials. 2006. PMID: 17170039 Review.
-
An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.Allergy. 2008 Jun;63(6):670-84. doi: 10.1111/j.1398-9995.2008.01723.x. Allergy. 2008. PMID: 18445184 Review.
Cited by
-
Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial.Pharmacoeconomics. 2006;24(5):443-52. doi: 10.2165/00019053-200624050-00003. Pharmacoeconomics. 2006. PMID: 16706570
-
Telemedicine Strategy for CPAP Titration and Early Follow-up for Sleep Apnea During COVID-19 and Post-Pandemic Future.Arch Bronconeumol. 2021 Apr;57:56-58. doi: 10.1016/j.arbres.2021.01.028. Epub 2021 Feb 13. Arch Bronconeumol. 2021. PMID: 34629654 Free PMC article. No abstract available.
-
The road not taken: transferability issues in multinational trials.Pharmacoeconomics. 2013 Oct;31(10):863-76. doi: 10.1007/s40273-013-0084-z. Pharmacoeconomics. 2013. PMID: 23979963
-
A Bayesian Framework for Patient-Level Partitioned Survival Cost-Utility Analysis.Med Decis Making. 2021 Nov;41(8):1033-1048. doi: 10.1177/0272989X211012348. Epub 2021 May 19. Med Decis Making. 2021. PMID: 34009065 Free PMC article.
-
The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.Pharmacoeconomics. 2007;25(8):649-64. doi: 10.2165/00019053-200725080-00003. Pharmacoeconomics. 2007. PMID: 17640107 Review.